SS-31 Peptide: Targeting the Powerhouse of the Cell

SS-31, also known as elamipretide or Bendavia, is a synthetic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2). Dr. Hazel Szeto developed it at Weill Cornell Medicine. It belongs to the Szeto-Schiller (SS) peptide family — cell-permeable, mitochondria-targeted peptides that concentrate in the inner mitochondrial membrane (IMM) with remarkable selectivity.

What makes SS-31 stand out is its targeting. Unlike most drugs that must navigate multiple cell compartments, SS-31 uses an electrochemical gradient to concentrate 5,000-fold within the IMM. This happens within minutes of dosing and does not depend on mitochondrial membrane potential. This means SS-31 reaches even damaged mitochondria that other targeted agents cannot access.

At the molecular level, SS-31 binds to cardiolipin — a phospholipid unique to the IMM that is essential for electron transport chain (ETC) function. Cardiolipin anchors cytochrome c to the IMM and maintains the structure of ETC complexes I, III, IV, and V.

When cardiolipin becomes oxidized (a hallmark of aging and disease), ETC efficiency collapses and ROS production rises. The cell enters a vicious cycle of mitochondrial decline. SS-31 stabilizes cardiolipin-cytochrome c interactions. It prevents cytochrome c peroxidase activity and restores efficient electron transport. For foundational peptide science, see our comprehensive peptide guide.

Mitochondrial dysfunction is now seen as a central driver of aging and age-related disease. The scope of this problem explains why SS-31 has drawn strong research interest.

The Scale of Mitochondrial Involvement: Human cells contain 1,000–2,000 mitochondria. Together they generate about 90% of cellular ATP through oxidative phosphorylation. Mitochondria also regulate calcium balance, apoptosis (programmed cell death), and cellular redox balance. When mitochondrial function declines, every energy-dependent cell process is affected — from muscle contraction to DNA repair.

Age-Related Decline: Mitochondrial function decreases about 10% per decade after age 30. By age 70, ATP production capacity may drop by 40–50% compared to young adults. This decline stems from oxidative damage to mitochondrial DNA (which lacks the strong repair tools of nuclear DNA), cardiolipin peroxidation, and declining mitophagy (the recycling of damaged mitochondria).

Disease Associations: Mitochondrial dysfunction is documented in heart failure, neurodegenerative diseases (Alzheimer's, Parkinson's), kidney disease, muscle wasting (sarcopenia), and metabolic syndrome. The mitochondrial theory of aging (Denham Harman, 1972) proposes that cumulative oxidative damage to mitochondria is a primary driver of aging itself.

The Treatment Gap: Before SS-31, no drug specifically targeted the inner mitochondrial membrane. Antioxidants like CoQ10 and vitamin E reduce systemic oxidative stress but do not concentrate enough in mitochondria to address localized cardiolipin oxidation.

MitoQ (a mitochondria-targeted CoQ10 derivative) reaches the mitochondrial matrix but does not directly stabilize cardiolipin-cytochrome c interactions. SS-31 fills this gap with precision no prior compound achieved.

SS-31 has been studied in over 200 preclinical studies and multiple clinical trials. The documented ss-31 peptide benefits span multiple organ systems.

Cardiac Function: In the phase 2 EMBRACE STEMI trial (297 patients with acute ST-elevation myocardial infarction), SS-31 given during reperfusion reduced infarct size by 13% versus placebo.

In heart failure models, SS-31 improved left ventricular ejection fraction by 15–20% and reduced cardiac fibrosis. A 2020 study in Circulation Research showed SS-31 normalized cardiac energetics in aged mice, restoring diastolic function to young-animal levels.

Skeletal Muscle: Age-related muscle loss (sarcopenia) is driven partly by mitochondrial dysfunction in myofibers. SS-31 in aged mice restored muscle mitochondrial content and improved exercise tolerance by 30%. A 2018 study in Aging Cell by Siegel et al. showed just 8 weeks of SS-31 reversed age-related declines in muscle mitochondrial function. ATP production capacity rose 30%.

Kidney Protection: SS-31 showed kidney-protective effects in multiple models of acute kidney injury (AKI) and chronic kidney disease (CKD). In ischemia-reperfusion AKI models, SS-31 reduced tubular necrosis by 60% and preserved mitochondrial membrane potential. The REPAIR trial (phase 2) showed elamipretide improved renal cortical blood flow in patients with atherosclerotic renal artery stenosis.

Ophthalmic Uses: The ReCLAIM trials evaluated elamipretide for age-related macular degeneration (AMD). ReCLAIM-2 (phase 2, 180 patients with dry AMD) showed improvements in low-luminance visual acuity and reduced drusen volume at 48 weeks. These results matter because no approved treatments exist for dry AMD. Explore more anti-aging peptide research in our peptide therapy guide.

Neurological Effects: Preclinical studies show SS-31 improves mitochondrial function in neurons and reduces oxidative stress in the hippocampus. Research in Neurobiology of Aging showed SS-31 reversed age-related synaptic loss and restored long-term potentiation — the cellular basis of memory formation.

SS-31's process is elegantly simple yet deeply effective. It targets the core biochemistry of mitochondrial energy production.

Cardiolipin Stabilization: SS-31 binds to cardiolipin through electrostatic interactions between its cationic residues (Arg, Lys) and cardiolipin's anionic phosphate groups. Hydrophobic interactions between its aromatic residues (Tyr, Phe) and cardiolipin's acyl chains also play a role. This binding prevents cardiolipin peroxidation and keeps the phospholipid able to anchor cytochrome c in its electron carrier form.

Cytochrome c Function Restoration: In healthy mitochondria, cytochrome c shuttles electrons between ETC complexes III and IV.

When cardiolipin is oxidized, cytochrome c shifts from an electron carrier to a peroxidase — an enzyme that creates ROS and triggers cell death.

SS-31 prevents this switch, keeping cytochrome c in its normal electron-carrying state (Birk et al., 2014, Journal of the American Chemical Society).

ETC Optimization: By stabilizing cardiolipin and cytochrome c function, SS-31 improves ETC coupling efficiency — the ratio of ATP produced per oxygen consumed. In aged mitochondria, coupling efficiency can drop by 30–40%. More oxygen is converted to ROS rather than used for ATP. SS-31 restores coupling to near-youthful levels, raising ATP production while reducing ROS output.

ROS Reduction Without Antioxidant Activity: Unlike standard antioxidants that scavenge ROS after they are produced, SS-31 prevents excess ROS at its source — the ETC. This is a key distinction. Antioxidant scavenging can interfere with normal ROS signaling.

SS-31's process normalizes ROS to healthy levels without disrupting redox signaling. Learn about other peptides that address oxidative stress in our skin peptide guide.

Research protocols for SS-31 vary by indication and study design. The following reflects published clinical and preclinical protocols — for research reference only.

Subcutaneous Injection: The most common research route. Clinical trials used doses of 4 mg, 20 mg, and 40 mg subcutaneously once daily. The EMBRACE STEMI trial used a single 0.05 mg/kg/hr IV infusion over 4 hours.

Preclinical studies typically use 1–5 mg/kg/day, with 3 mg/kg being the most cited dose in aging research. Half-life is about 4 hours, supporting daily dosing for sustained mitochondrial protection.

Duration: Clinical trial durations range from single dose (acute myocardial infarction) to 48 weeks (AMD studies). Aging research in animal models typically uses 4–8 week periods. Siegel et al. showed clear reversal of age-related mitochondrial decline after 8 weeks of daily SS-31 in aged mice. Extended studies (12+ months) are underway to assess long-term safety.

Reconstitution: SS-31 is typically supplied as a lyophilized powder. Reconstitute with sterile water or bacteriostatic water. It is fairly stable in solution when stored at 2–8°C, keeping potency for 14–28 days post-reconstitution. Use our peptide calculator for precise reconstitution volumes.

Timing: In exercise studies, SS-31 is given 30–60 minutes before exercise for peak mitochondrial concentration during peak energy demand. For aging research, morning dosing aligns with the daily peak in mitochondrial biogenesis signaling (PGC-1α expression). In cardiac studies, timing is critical — maximal heart protection in ischemia-reperfusion models requires SS-31 presence before reperfusion onset.

SS-31 (elamipretide) has shown a favorable safety profile across multiple clinical trials.

Clinical Safety Data: In the EMBRACE STEMI trial (297 patients), elamipretide showed no notable safety signals versus placebo. The most common adverse events were injection site reactions (5–10%) and mild headache (3–5%).

No dose-limiting toxicities were seen at doses up to 40 mg daily in phase 1 trials. The ReCLAIM AMD trials (48 weeks of daily dosing) reported no treatment-related serious adverse events.

Long-Term Safety: Animal studies using SS-31 at 5 mg/kg/day for 26 weeks showed no organ toxicity, no reproductive effects, and no genotoxicity. The compound is rapidly broken down by peptidases, producing natural amino acid metabolites.

No drug buildup is seen with repeated daily dosing. SS-31 does not impair normal mitochondrial function in healthy cells. It specifically targets pathological cardiolipin oxidation.

No Mitochondrial Uncoupling: Unlike some mitochondria-targeted compounds (e.g., FCCP, DNP), SS-31 does not uncouple oxidative phosphorylation. This is a key safety point. Uncoupling can generate dangerous heat and deplete cellular ATP. SS-31 improves coupling efficiency without changing the core thermodynamic link between electron transport and ATP production.

Drug Interactions: No notable drug interactions have been reported. SS-31 is not broken down by cytochrome P450 enzymes, removing a major source of drug interactions. It does not affect hepatic or renal drug clearance pathways.

Theoretical caution is warranted when pairing SS-31 with drugs that affect mitochondrial function (e.g., metformin, statins) until combination safety data is available. Learn about peptide quality evaluation on our about page.

SS-31's potential as an anti-aging intervention is arguably its most exciting research use. Mitochondrial dysfunction plays a central role in aging.

Reversal of Age-Related Changes: A landmark 2018 study by Campbell et al. in Aging Cell showed that 8 weeks of SS-31 in 26-month-old mice (about 78 human years) reversed multiple age-related mitochondrial changes. ATP production capacity rose 30%.

ROS output dropped 50%. Mitochondrial proton leak (a hallmark of aging) normalized. Exercise endurance improved by 20%. These changes lasted at least 2 weeks after stopping treatment. This suggests durable mitochondrial remodeling, not just a transient drug effect.

Epigenetic Rejuvenation: Research in Geroscience (2021) found SS-31 reversed about 10% of age-related DNA methylation changes in skeletal muscle. This effectively shifted the epigenetic clock toward a younger state. While 10% reversal is modest, it proves that mitochondrial restoration can influence the epigenetic aging process.

Proteostasis Improvement: Mitochondrial ATP powers the proteasome and autophagy systems that clear damaged proteins. SS-31's restoration of ATP production indirectly improves protein quality control. In aged models, SS-31 raised proteasomal activity by 25% and autophagic flux by 40%. This reduced the buildup of protein aggregates linked to neurodegeneration and cellular senescence.

Stem Cell Rejuvenation: A 2022 study in Cell Stem Cell showed SS-31 improved the regenerative capacity of aged muscle stem cells (satellite cells) by restoring their mitochondrial function. Treated aged satellite cells showed improved self-renewal and differentiation.

This suggests mitochondrial restoration may rejuvenate the body's tissue repair machinery. For more on regenerative peptide research, see our bioactive peptides overview.

SS-31's unique mitochondrial targeting makes it complementary to peptides that address other aspects of cellular aging and tissue repair.

SS-31 + NAD+ Precursors (NMN/NR): NAD+ is a critical mitochondrial cofactor that declines with age. NAD+ precursors restore the cofactor supply. SS-31 optimizes the mitochondrial machinery that uses NAD+. This combo addresses both the fuel (NAD+) and the engine (ETC efficiency) of mitochondrial energy production. Preclinical data suggests additive benefits on cellular energetics.

SS-31 + GHK-Cu: GHK-Cu turns on genes involved in antioxidant defense and tissue remodeling. SS-31 prevents mitochondrial ROS production at the source. Together, they provide complete oxidative stress management. SS-31 handles intracellular (mitochondrial) ROS. GHK-Cu boosts extracellular and nuclear antioxidant defenses. Learn more about GHK-Cu peptide benefits.

SS-31 + Epithalon: Epithalon activates telomerase to maintain cell division capacity. SS-31 ensures those dividing cells have healthy mitochondria. This combo addresses both replicative aging (telomere shortening) and metabolic aging (mitochondrial decline).

SS-31 + Exercise: Exercise is itself a potent trigger for mitochondrial biogenesis (via PGC-1α activation). SS-31 optimizes existing mitochondrial function while exercise generates new mitochondria. Research in aged mice shows SS-31 + exercise produces greater improvements in aerobic capacity than either alone. Giving SS-31 30–60 minutes before exercise may maximize the combined benefit.

All stacking protocols should include proper monitoring and controls. The interaction profiles between SS-31 and most research peptides are not yet fully mapped. A conservative approach is advisable. Research listings—verify batch docs with sellers; we don’t certify purity.

SS-31 appears in both pharmaceutical development channels and research catalogs. Laboratories should insist on sequence confirmation for the D-Arg-dimethylTyr-Lys-Phe-NH2 scaffold, potency testing relevant to the planned assay, and endotoxin screening before in vivo work. Because SS-31 concentrates in mitochondria, small impurities can disproportionately affect bioenergetic readouts—treat low nanomolar assays with extra analytical rigor.

Use COA literacy guides, research sourcing hub, and MOTS-c comparison when documenting why a given lot was accepted. PurePep does not perform independent verification.